Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protara Therapeutics, Inc. (TARA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Protara is a clinical-stage biotechnology company listed on The Nasdaq Global Market under the symbol TARA, and its filings offer insight into the development of its investigational therapies TARA-002 and IV Choline Chloride, as well as its capital raising activities.
Among the key documents available are Form 8-K current reports, where Protara reports material events such as public offerings of common stock under its shelf registration statement on Form S-3, interim clinical data from the Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), and interim results from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations (LMs). These filings also describe regulatory feedback from the U.S. Food and Drug Administration (FDA) on registrational trial designs and summarize safety and efficacy data disclosed in associated press releases and investor presentations.
Investors can also use this page to track financing-related disclosures, including details of underwritten public offerings, the number of shares issued, gross proceeds, and the intended use of net proceeds, which Protara states include funding the clinical development of TARA-002 and other clinical programs, as well as working capital and general corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of clinical updates, regulatory interactions, and financing transactions. Real-time updates from EDGAR mean that new Protara filings, such as additional 8-Ks, quarterly or annual reports when filed, and other registration statements, can be reviewed soon after submission.
For users interested in governance and ownership details, this page also serves as a starting point to locate information typically found in periodic and transactional filings, while AI-generated overviews can make complex regulatory language more accessible to a broader audience.
On August 11, 2025, Protara Therapeutics, Inc. announced that it released its financial results for the quarter ended June 30, 2025 via a press release attached as Exhibit 99.1 to this Form 8-K. The filing explicitly states the press release and related information are being furnished and shall not be deemed filed under the Exchange Act or incorporated by reference into other filings unless expressly stated. The 8-K lists Exhibits 99.1 and 104 and is signed by Chief Financial Officer Patrick Fabbio. No financial figures or operating metrics appear in the 8-K text; readers must consult Exhibit 99.1 for the detailed results.